Hem Pharma, Inc.

As of June 30, 2026, Hem Pharma, Inc. carries a market capitalization of 325.44B, placing it among publicly traded companies globally. Its enterprise value stands at 336.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hem Pharma, Inc.'s next confirmed earnings release is scheduled for November 27, 2026.

As of June 30, 2026, Hem Pharma, Inc. has 7.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 20.03, and the price-to-book ratio stands at 22.49.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 336.95B versus a market cap of 325.44B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hem Pharma, Inc. maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 119.10, indicating elevated leverage, while an interest coverage ratio of -10.65 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hem Pharma, Inc. posted a negative return on equity (ROE) of -115.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -44.71, reflecting losses generated across the asset base. The company generates approximately 165.99M in revenue per employee across its workforce of 97.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.28 indicates how many times Hem Pharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hem Pharma, Inc. recorded an income tax benefit of -3.18B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -23.92B and -20.81B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Hem Pharma, Inc.'s stock has declined approximately 5.91% over the past 52 weeks. The 50-day moving average sits at 35,700.00, while the 200-day moving average is 53,278.00.

Over the twelve months ended June 30, 2026, Hem Pharma, Inc. generated 16.14B in revenue and converted that into -20.81B in net income, yielding earnings per share of -2,909.07. EBITDA reached -14.27B, while operating income came in at -17.02B.

As of June 30, 2026, Hem Pharma, Inc. holds 9.56B in cash and equivalents against 19.32B in total debt, resulting in a net debt position of 10.09B. Total book value stands at 14.47B, with working capital of -12.07B providing operational flexibility.

Hem Pharma, Inc. produced -7.42B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.66B in capital expenditures, free cash flow totaled -19.09B - equivalent to -2,677.13 per share.

Over the twelve months ended June 30, 2026, Hem Pharma, Inc. posted a gross margin of 12.93, reflecting its pricing power and cost economics. The operating margin of -105.44 and net profit margin of -128.91 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.65, meaning Hem Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Hem Pharma, Inc. has an Altman Z-Score of 1.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.